Abstract
Microglia are the resident macrophages of the central nervous system (CNS). Gene expression profiling has identified Sall1, which encodes a transcriptional regulator, as a microglial signature gene. We found that Sall1 was expressed by microglia but not by other members of the mononuclear phagocyte system or by other CNS-resident cells. Using Sall1 for microglia-specific gene targeting, we found that the cytokine receptor CSF1R was involved in the maintenance of adult microglia and that the receptor for the cytokine TGF-β suppressed activation of microglia. We then used the microglia-specific expression of Sall1 to inducibly inactivate the murine Sall1 locus in vivo, which resulted in the conversion of microglia from resting tissue macrophages into inflammatory phagocytes, leading to altered neurogenesis and disturbed tissue homeostasis. Collectively, our results show that transcriptional regulation by Sall1 maintains microglial identity and physiological properties in the CNS and allows microglia-specific manipulation in vivo.
This is a preview of subscription content, access via your institution
Access options
Similar content being viewed by others
Accession codes
Change history
28 November 2016
In the HTML version of this article initially published, the scale bar was missing from the inset in the top right image in Figure 2d; the bottom left plot in Figure 2e was incorrectly a duplicate of the adjacent plot at right; and the designations in Figure 4b (Sall1fl and Sall1creER/fl) should have been Sall1fl/fl and Sall1CreER/fl (respectively). Also, the arrows in the designations above and below the plots in Supplementary Figure 3b were rendered as boxes; these should have been as follows: Sall1+/+→Cx3cr1CreER-iDTR and Sall1GFP/+→Cx3cr1CreER-iDTR. Finally, in Supplementary Figure 4f, the red (Ki67+) cells in the right set of images were not visible. These errors have been corrected for the HTML version of this article.
References
Ajami, B., Bennett, J.L., Krieger, C., Tetzlaff, W. & Rossi, F.M. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci. 10, 1538–1543 (2007).
Ginhoux, F. et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841–845 (2010).
Hashimoto, D. et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 38, 792–804 (2013).
Gomez Perdiguero, E. et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 518, 547–551 (2015).
Hoeffel, G. et al. C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity 42, 665–678 (2015).
Kierdorf, K. et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat. Neurosci. 16, 273–280 (2013).
Schulz, C. et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336, 86–90 (2012).
Greter, M. et al. Stroma-derived interleukin-34 controls the development and maintenance of langerhans cells and the maintenance of microglia. Immunity 37, 1050–1060 (2012).
Butovsky, O. et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat. Neurosci. 17, 131–143 (2014).
Wu, Y., Dissing-Olesen, L., MacVicar, B.A. & Stevens, B. Microglia: dynamic mediators of synapse development and plasticity. Trends Immunol. 36, 605–613 (2015).
Shemer, A., Erny, D., Jung, S. & Prinz, M. Microglia plasticity during health and disease: an immunological perspective. Trends Immunol. 36, 614–624 (2015).
Lavin, Y. et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159, 1312–1326 (2014).
Gosselin, D. et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell 159, 1327–1340 (2014).
Gautier, E.L. et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. 13, 1118–1128 (2012).
Yamasaki, R. et al. Differential roles of microglia and monocytes in the inflamed central nervous system. J. Exp. Med. 211, 1533–1549 (2014).
Bennett, M.L. et al. New tools for studying microglia in the mouse and human CNS. Proc. Natl. Acad. Sci. USA 113, E1738–E1746 (2016).
Koso, H. et al. Conditional rod photoreceptor ablation reveals Sall1 as a microglial marker and regulator of microglial morphology in the retina. Glia 64, 2005–2024 (2016).
Sweetman, D. & Münsterberg, A. The vertebrate spalt genes in development and disease. Dev. Biol. 293, 285–293 (2006).
Karantzali, E. et al. Sall1 regulates embryonic stem cell differentiation in association with nanog. J. Biol. Chem. 286, 1037–1045 (2011).
Harrison, S.J., Nishinakamura, R., Jones, K.R. & Monaghan, A.P. Sall1 regulates cortical neurogenesis and laminar fate specification in mice: implications for neural abnormalities in Townes-Brocks syndrome. Dis. Model. Mech. 5, 351–365 (2012).
Nishinakamura, R. et al. Murine homolog of SALL1 is essential for ureteric bud invasion in kidney development. Development 128, 3105–3115 (2001).
Kohlhase, J. SALL1 mutations in Townes-Brocks syndrome and related disorders. Hum. Mutat. 16, 460–466 (2000).
Vodopiutz, J. et al. Homozygous SALL1 mutation causes a novel multiple congenital anomaly-mental retardation syndrome. J. Pediatr. 162, 612–617 (2013).
Inoue, S., Inoue, M., Fujimura, S. & Nishinakamura, R. A mouse line expressing Sall1-driven inducible Cre recombinase in the kidney mesenchyme. Genesis 48, 207–212 (2010).
Takasato, M. et al. Identification of kidney mesenchymal genes by a combination of microarray analysis and Sall1-GFP knockin mice. Mech. Dev. 121, 547–557 (2004).
Abedin, M.J., Imai, N., Rosenberg, M.E. & Gupta, S. Identification and characterization of Sall1-expressing cells present in the adult mouse kidney. Nephron Exp. Nephrol. 119, e75–e82 (2011).
Hirsch, S. et al. A mouse model of Townes-Brocks syndrome expressing a truncated mutant Sall1 protein is protected from acute kidney injury. Am. J. Physiol. Renal Physiol. 309, F852–F863 (2015).
Goldmann, T. et al. Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat. Immunol. 17, 797–805 (2016).
Varvel, N.H. et al. Microglial repopulation model reveals a robust homeostatic process for replacing CNS myeloid cells. Proc. Natl. Acad. Sci. USA 109, 18150–18155 (2012).
Bruttger, J. et al. Genetic cell ablation reveals clusters of local self-renewing microglia in the mammalian central nervous system. Immunity 43, 92–106 (2015).
Elmore, M.R. et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 82, 380–397 (2014).
Schreiner, B., Heppner, F.L. & Becher, B. Modeling multiple sclerosis in laboratory animals. Semin. Immunopathol. 31, 479–495 (2009).
Croxford, A.L. et al. The Cytokine GM-CSF drives the inflammatory signature of CCR2+ monocytes and licenses autoimmunity. Immunity 43, 502–514 (2015).
Waisman, A., Ginhoux, F., Greter, M. & Bruttger, J. Homeostasis of microglia in the adult brain: review of novel microglia depletion systems. Trends Immunol. 36, 625–636 (2015).
Remington, L.T., Babcock, A.A., Zehntner, S.P. & Owens, T. Microglial recruitment, activation, and proliferation in response to primary demyelination. Am. J. Pathol. 170, 1713–1724 (2007).
Chiu, I.M. et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 4, 385–401 (2013).
Yona, S. et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38, 79–91 (2013).
Goldmann, T. et al. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat. Neurosci. 16, 1618–1626 (2013).
Surace, M.J. & Block, M.L. Targeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors. Cell. Mol. Life Sci. 69, 2409–2427 (2012).
Ikushima, H., Negishi, H. & Taniguchi, T. The IRF family transcription factors at the interface of innate and adaptive immune responses. Cold Spring Harb. Symp. Quant. Biol. 78, 105–116 (2013).
Ivashkiv, L.B. & Donlin, L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36–49 (2014).
Kimura, A. et al. Aryl hydrocarbon receptor protects against bacterial infection by promoting macrophage survival and reactive oxygen species production. Int. Immunol. 26, 209–220 (2014).
Fourgeaud, L. et al. TAM receptors regulate multiple features of microglial physiology. Nature 532, 240–244 (2016).
Kempermann, G., Jessberger, S., Steiner, B. & Kronenberg, G. Milestones of neuronal development in the adult hippocampus. Trends Neurosci. 27, 447–452 (2004).
Ginhoux, F. & Jung, S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat. Rev. Immunol. 14, 392–404 (2014).
Gemma, C. & Bachstetter, A.D. The role of microglia in adult hippocampal neurogenesis. Front. Cell. Neurosci. 7, 229 (2013).
Ohmori, T., Tanigawa, S., Kaku, Y., Fujimura, S. & Nishinakamura, R. Sall1 in renal stromal progenitors non-cell autonomously restricts the excessive expansion of nephron progenitors. Sci. Rep. 5, 15676 (2015).
Yamashita, K., Sato, A., Asashima, M., Wang, P.C. & Nishinakamura, R. Mouse homolog of SALL1, a causative gene for Townes-Brocks syndrome, binds to A/T-rich sequences in pericentric heterochromatin via its C-terminal zinc finger domains. Genes Cells 12, 171–182 (2007).
Hoeffel, G. et al. Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages. J. Exp. Med. 209, 1167–1181 (2012).
Zhang, Y. et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 89, 37–53 (2016).
Parkhurst, C.N. et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155, 1596–1609 (2013).
Yuri, S. et al. Sall4 is essential for stabilization, but not for pluripotency, of embryonic stem cells by repressing aberrant trophectoderm gene expression. Stem Cells 27, 796–805 (2009).
Li, J., Chen, K., Zhu, L. & Pollard, J.W. Conditional deletion of the colony stimulating factor-1 receptor (c-fms proto-oncogene) in mice. Genesis 44, 328–335 (2006).
Levéen, P. et al. TGF-beta type II receptor-deficient thymocytes develop normally but demonstrate increased CD8+ proliferation in vivo. Blood 106, 4234–4240 (2005).
Jung, S. et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 20, 4106–4114 (2000).
Buch, T. et al. A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat. Methods 2, 419–426 (2005).
Greter, M. et al. GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity 36, 1031–1046 (2012).
Acknowledgements
We thank V. Tosevski and F. Mair for technical help and flow cytometry sorting; J. Jaberg, S. Nemetz and J. Candreia for technical support; A.L. Croxford for critical reading of the manuscript; S. Jessberger, B. Schreiner and C. Raposo for critical discussions; J.K. Georgijevic and W. Qi for performing the next generation sequencing analysis at the Functional Genomics Centre Zurich (FGCZ); Plexxikon (P. Singh and B. West) for PLX5622-containing and control diets; and the Neuroscience Center Zürich, and the Microbiology and Immunology PhD program, University of Zurich and ETH, Zurich, Switzerland. Cx3cr1CreER were kindly provided by S. Jung (Weizmann Institute of Science). Csf1rfl/fl mice were kindly provided by J. Pollard (Albert Einstein College of Medicine). Supported by the Swiss National Science Foundation (BSSGI0_155832, PP00P3_144781, 316030 150768, 310030 146130, and CRSII3 136203 for M.G. and B.B.), the Swiss Multiple Sclerosis Society (M.G. and B.B.), the European Union FP7 project TargetBraIn, NeuroKine, ATECT (B.B.), the National Agency of Research (LIPOCAMD and MACLEAR for E.L.G.) and the Fondation de France (00056835 for E.L.G.).
Author information
Authors and Affiliations
Contributions
A.B. and M.G. designed the study, performed experiments and wrote the manuscript; R.N. provided the Sall1 strains; M.V., X.Y., N.R.K. and I.L. performed experiments; E.L.G. analyzed microarray data (Immgen); and B.B. designed experiments and co-wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Integrated supplementary information
Supplementary Figure 1 Sall1 expression is restricted to microglia within the hematopoietic system.
(a) Flow cytometry plots show representative pre-gating strategy for CD45+ cells (shown are CNS cells). (b) Flow cytometry analysis of GFP (Sall1) expression in different organs of Sall1GFP/+ and Sall1+/+ (control) mice (pre-gated on CD45+ cells as in a. (c) qPCR analysis of Sall1 mRNA in sorted cell populations derived from WT mice; results were normalized to Pol2 expression. Alveolar MFs: CD45+Siglec-F+CD11c+, Lung CD11b+ DCs: CD45+Siglec-F−CD11c+MHCII+CD11b+, Lung CD103+ DCs: CD45+Siglec-F−CD11c+MHCII+CD103+, SP MF (spleen macrophages): F4/80hiCD11b+, SP NPs (spleen neutrophils): Ly6G+SSChi, BM Mo (BM monocytes): Lin−CD11b+Ly6C+CD115+, microglia: CD45loLy6C−Ly6G−CD11b+F4/80+, Per. B cells (peritoneal B cells): B220+, Per. (peritoneal) MFs: CD115+CD11b+F4/80+. (d) qPCR analysis of Sall1 mRNA in total tissue lysates of different organs; results were normalized to Pol2 expression. (e) Representative flow cytometry plots of kidney, liver and heart of Sall1GFP/+ mice (pre-gated on CD45− cells). (f) Quantification of results in e, presented as frequency of GFP+ (Sall1) cells; each symbol represents an individual mouse; small horizontal lines indicate the mean (± s.e.m.). Data are representative of 2-4 mice per genotype, 2 experiments (b); 2 samples per population pooled from 2-3 WT mice, 2 experiments (c; mean ± s.e.m.); 13 (spleen), 12 (brain), 11 (kidney, liver), 9 (spinal cord), 7 (lung, heart), 4 (skin), 3 (lymph node) WT mice, 2-5 experiments, 1 experiment (lymph node) (d; mean ± s.e.m.); 6 (liver), 5 (kidney, heart) Sall1GFP/+ mice, 2 experiments (e,f).
Supplementary Figure 2 Sall1 expression is specific to resident microglia within the adult CNS.
(a) IHC of brain sections of Sall1GFP/+ mice, showing GFP (green), DAPI (blue), and GFAP (radial-glia-like stem cells), DCX (neuroblasts), Calbindin (Purkinje neurons), S100B (astrocytes) or MBP (oligodendrocytes) (red); insets (without DAPI; top right) are enlargements of the outlined areas in the main images. Scale bars, 20 μm (main image) or 5 μm (insets). (b) Gating strategy of non-hematopoietic (CD45−) CNS-resident cells and representative flow cytometry plots for their GFP expression in Sall1GFP/+ mice. (c) Quantification of results in b, presented as frequency of GFP+ cells. Each symbol represents an individual mouse; small horizontal lines indicate the mean (± s.e.m.). *P < 0.0001 (one-way ANOVA). (d) Gating strategy of CNS-resident myeloid cells and separately isolated choroid plexus (CP) cells. Representative flow cytometry plots display the percentage of GFP+ cells in Sall1GFP/+ mice. MF: Macrophage. (e) IHC of brain sections of Sall1GFP/+ mice, showing GFP (green), DAPI (blue), Iba-1 or F4/80 (microglia and CNS-MF) (red) and CD31 (endothelial cells) (gray); arrowheads indicate Iba-1 and GFP or F4/80 and GFP double-positive microglia; insets (without DAPI; top right) are enlargements of the outlined areas in the main images. Scale bars, 20 μm (main image) or 5 μm (insets). Data are representative of 2-3 mice per staining, 2 experiments (a); 3 mice, 1 experiment (b,c); 6 mice, 2 experiments (d); 2-3 mice per staining, 2 experiments (e).
Supplementary Figure 3 CNS-infiltrating myeloid cells and BM-derived microglia and/or macrophages do not express Sall1.
(a) Frequency of GFP+ microglia and CD45hi MF of Sall1GFP/+ and Cx3cr1GFP/+ reporter mice and of YFP+ or RFP+ microglia and CD45hi MFs in tamoxifen treated Sall1CreERR26-YFP or Cx3cr1CreERR26-RFP mice. Microglia: CD45loCD11b+F4/80+Ly6C−Ly6G−, CD45hi MFs: CD45hiCD11b+F4/80+Ly6C−Ly6G−. (b) Flow cytometry analysis and quantification of the frequency of GFP+ microglia in tamoxifen- and diphtheria toxin-treated Sall1+/+(CD45.1)→Cx3cr1CreER-iDTR(CD45.2) or Sall1GFP/+(CD45.1)→Cx3cr1CreER-iDTR(CD45.2) BM chimeras on day 0, 11 and 21 after treatment (pre-gated on CD11b+F4/80+CD45.1loLy6C−Ly6G− cells) or in untreated Sall1GFP/+ (control) mice. (c) Representative histograms and quantification of GFP expression in monocyte-derived cells (MCs) (gated on CD45hiCD11b+CD11c+MHCII+Ly6C+), neutrophils (gated on CD45hiCD11b+ Ly6G+), CD4+ T cells (gated on CD45hiCD11b-CD4+) and microglia (gated on CD45loLy6C-Ly6G-CD11b+) in Sall1GFP/+ mice at peak disease of MOG35-55/CFA-induced EAE. Each symbol (a-c) represents an individual mouse; small horizontal lines (a-c) indicate the mean (± s.e.m.). *P < 0.0001 (one-way ANOVA). Data are representative of 15 (Sall1GFP/+), 10 (Sall1CreERR26-YFP, Cx3cr1CreERR26-RFP), 4 (Cx3cr1GFP/+) mice, at least 2 experiments (a); 4 mice (d11, d21), 2 experiments and 1 mouse (d0, untreated Sall1GFP/+) (b); 7 (microglia), 5 (MCs, Neutrophils, CD4+ T cells) mice, 3 experiments (c).
Supplementary Figure 4 Microglia-specific targeting utilizing Sall1CreER mice.
(a) Flow cytometry analysis of Sall1CreERR26-YFP mice and R26-YFP (control) littermates on day 3 after 5 consecutive days of tamoxifen treatment, showing the frequency of YFP+ microglia (pre-gated on CD45loLy6G−Ly6C−CD11b+). (b) IHC of cortical brain sections of Sall1CreERCsf1rfl/fl and Csf1rfl/fl mice at day 0, 7 and 14 after 5 consecutive days of tamoxifen treatment, showing Iba-1 (microglia) (green) and DAPI (blue). Scale bar, 20 μm. Quantification shows microglia counts in different brain areas at day 0 after tamoxifen treatment. (c) qPCR analysis of Tgfbr2 mRNA in microglia sorted from Sall1CreERTgfbr2fl/fl and Tgfbr2fl/fl mice on day 0 after three consecutive days of tamoxifen treatment; results were normalized to Pol2 expression. (d) Histograms display the expression of different surface markers vs. FMO on microglia of Sall1CreERTgfbr2fl/fl and Tgfbr2fl/fl mice as in c on day 6 after tamoxifen treatment. (e) Quantification of microglia numbers in Sall1CreERTgfbr2fl/fl and Tgfbr2fl/fl mice as in c on day 0, 3 and 6 after tamoxifen treatment. Numbers are displayed as ratios to control (Tgfbr2fl/fl) mice. (f) IHC of brain sections from Sall1CreERTgfbr2fl/fl and Tgfbr2fl/fl mice as in c analyzed on day 3 after tamoxifen treatment, showing Iba-1 (green), Ki67 (red) and DAPI (blue). Arrowheads indicate Iba-1 and Ki67 double-positive cells. Scale bar, 50 μm. Each symbol (b,e) represents an individual mouse. ns = not significant, * p < 0.05, ** p < 0.01, *** p < 0.001 (unpaired t-test). Data are representative of 10 mice, 5 experiments (a); 3-5 sections of 2 mice, 2 experiments (b; mean ± s.e.m.); 1 pooled sample of 3-4 mice per genotype (c); 2-5 mice per genotype, at least 2 experiments (d); 4 (d0), 3 (d3), 5-6 (d6) mice, 2 experiments (e; mean ± s.e.m.); 1-2 mice per genotype (f).
Supplementary Figure 5 Gene expression profile of Sall1-deficient microglia.
(a-c) Gene expression analysis of microglia sorted from Sall1CreER/fl and Sall1fl/fl mice on day 1 after 5 times of tamoxifen treatment every second day as described in Figure 4. (a) Venn diagram of differentially expressed genes. (b) Volcano plot showing log2 ratios vs. p values (log10) of all 12,673 detected genes. Genes with highest significance values are annotated. (c) Expression (log2 ratio) of Sall1-regulated genes clustered according to their indicated GO-pathways; IS, Immune system; (bold indicates genes discussed in Results). (d) Multiplex immunoassays show levels (pg/mg) of IL-1, IL-6, TNF-α and IL-10 in serum and whole tissue lysates of spleen, kidney and liver of untreated (control) mice and Sall1CreER/fl and Sall1fl/fl mice at day 6 after start of tamoxifen treatment. (e) Graph displays cell counts of DCX+ neuroblasts in hippocampal brain sections of tamoxifen treated Cx3cr1CreERSall1fl/fl and Cre− (control) littermates; each symbol represents an individual mouse; small horizontal lines indicate the mean (± s.e.m.). * p = 0.0006 (unpaired t-test). Data are representative of 3-5 mice pooled per genotype and biological replicate, 3 experiments (a-c); 3 (Sall1CreER/fl, Sall1fl/fl), 2 (untreated) mice, 1 experiment (d; mean ± s.e.m.); 3 (Cx3cr1CreERSall1fl/fl), 4 (control) mice, 2 experiments (e).
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–5 (PDF 4088 kb)
Rights and permissions
About this article
Cite this article
Buttgereit, A., Lelios, I., Yu, X. et al. Sall1 is a transcriptional regulator defining microglia identity and function. Nat Immunol 17, 1397–1406 (2016). https://doi.org/10.1038/ni.3585
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni.3585
This article is cited by
-
Border-associated macrophages in the central nervous system
Journal of Neuroinflammation (2024)
-
The roles of tissue resident macrophages in health and cancer
Experimental Hematology & Oncology (2024)
-
Advanced patient-specific microglia cell models for pre-clinical studies in Alzheimer’s disease
Journal of Neuroinflammation (2024)
-
Transcriptional characterization of iPSC-derived microglia as a model for therapeutic development in neurodegeneration
Scientific Reports (2024)
-
The molecular determinants of microglial developmental dynamics
Nature Reviews Neuroscience (2024)